ArticleInternational journal of gastrointestinal cancer2006
Characterization of the CXCR4 signaling in pancreatic cancer cells.
Article in International journal of gastrointestinal cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.PloS one · 2015Pooled it
- Article
- The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets.Frontiers in oncology · 2023Review
- Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer.Oncology reports · 2022Article
- Understanding pancreatic cancer stem cells and their role in carcinogenesis: a narrative review.Stem cell investigation · 2022Review
- Article
- Translational challenges in pancreatic neuroendocrine tumor immunotherapy.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Chronic Pancreatitis and the Development of Pancreatic Cancer.Endocrine, metabolic & immune disorders drug targets · 2020Review
- Trefoil factor 2 activation of CXCR4 requires calcium mobilization to drive epithelial repair in gastric organoids.The Journal of physiology · 2019Article
- Ping-Pong-Tumor and Host in Pancreatic Cancer Progression.Frontiers in oncology · 2019Review
- Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.International journal of clinical oncology · 2017Review
- Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.Pharmacology & therapeutics · 2017Review
- Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis.Journal of experimental & clinical cancer research : CR · 2017Article
- Adipocytes enhance expression of osteoclast adhesion-related molecules through the CXCL12/CXCR4 signalling pathway.Cell proliferation · 2017Article
- Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas.Oncology letters · 2017Article
- Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells.Oncotarget · 2017Article
- Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers.Journal of immunology research · 2017Review
- Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer.Molecular biology of the cell · 2016Article
- Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts.American journal of cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
CXCL12 and its receptor, CXCR4, are emerging as promising targets for modulating growth, angiogenesis, and metastasis in several human cancers. Indeed, blocking the receptor is sufficient to prevent metastasis and angiogenesis in experimental breast cancer xenografts. Recently, the biological effect of the CXCR4 in pancreatic cancer, one of the most deadly neoplastic diseases, has been reported. However, the molecular mechanism by which CXCR4 contributes to these properties is not completely understood. In this paper, we characterize the signaling pathways activated by CXCR4 in pancreatic cancer. We show that after CXCR4 activation, EGFR becomes tyrosine phosphorylated, and the kinase activity of this receptor, together with the activation of MMPs, Src, and PI3-Kinase, is required for CXCR4-mediated ERK activation. Analysis of this cascade in pancreatic cancer cells revealed that the ERK-mediated pathway regulates genes involved in angiogenesis, such as VEGF, CD44, HIF1alpha, and IL-8. Furthermore, ERK blockage inhibits the migration and tube formation of endothelial cells induced by CXCL12. Considering that inhibitors for several components of this pathway, including CXCR4 itself, are at different stages of clinical trials, this study provides theoretical justification for the clinical testing of these drugs in pancreatic cancer, thus extending the list of potential targets for treating this dismal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.